{"protocolSection":{"identificationModule":{"nctId":"NCT00316225","orgStudyIdInfo":{"id":"10426"},"secondaryIdInfos":[{"id":"H3E-MC-JMHX","type":"OTHER","domain":"Eli Lilly and Company"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"Study of Pemetrexed in Mesothelioma and Lung Cancer Patients With Fluid Around the Lungs or Abdomen","officialTitle":"A Phase 2 Study of ALIMTA in Solid Tumor Patients With Stable Third-Space Fluid"},"statusModule":{"statusVerifiedDate":"2010-06","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2006-12"},"primaryCompletionDateStruct":{"date":"2009-03","type":"ACTUAL"},"completionDateStruct":{"date":"2009-03","type":"ACTUAL"},"studyFirstSubmitDate":"2006-04-18","studyFirstSubmitQcDate":"2006-04-18","studyFirstPostDateStruct":{"date":"2006-04-20","type":"ESTIMATED"},"resultsFirstSubmitDate":"2010-03-10","resultsFirstSubmitQcDate":"2010-06-10","resultsFirstPostDateStruct":{"date":"2010-07-09","type":"ESTIMATED"},"lastUpdateSubmitDate":"2010-06-10","lastUpdatePostDateStruct":{"date":"2010-07-09","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"oldNameTitle":"Chief Medical Officer","oldOrganization":"Eli Lilly"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"This study will test the effects of pemetrexed on mesothelioma and non-small cell lung cancer patients with fluid around their lungs or abdomen."},"conditionsModule":{"conditions":["Non-small Cell Lung Cancer","Mesothelioma","Lung Neoplasms"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":31,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Pemetrexed","type":"EXPERIMENTAL","description":"Pemetrexed 500 mg/m\\^2 intravenous (IV) every 21 days for 6 cycles","interventionNames":["Drug: pemetrexed"]}],"interventions":[{"type":"DRUG","name":"pemetrexed","description":"500 milligrams per meter squared (mg/m\\^2) IV every 21 days for 6 cycles","armGroupLabels":["Pemetrexed"],"otherNames":["LY231514","Alimta"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Overview of Adverse Events","description":"Any untoward medical occurrence in a patient who received study drug was considered an adverse event (AE), without regard to possibility of causal relationship. Treatment-emergent adverse events (TEAE): those which occurred or worsened after baseline. An adverse event resulting in any of the following outcomes, or deemed to be significant for any other reason, was considered to be a serious adverse event (SAE): death; initial or prolonged inpatient hospitalization; a life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.","timeFrame":"baseline, up to 18 weeks"}],"secondaryOutcomes":[{"measure":"Number of Participants With Common Toxicity Criteria - National Cancer Institute Grade 3 and Grade 4 Toxicities","description":"Number of participants with laboratory and non-laboratory toxicities possibly related to study drug, which were graded using the Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0) for defining and grading specific adverse events. Grades range from 0 (none) to 5 (death). Grade 3 is severe and Grade 4 is life-threatening.\n\nNOS = Not otherwise specified.","timeFrame":"baseline, up to 18 weeks"},{"measure":"Pemetrexed Population Pharmacokinetics (PK): Clearance","description":"Clearance (CL) can be defined as the volume of plasma which is completely cleared of drug (pemetrexed) per unit time. Total body clearance is calculated after intravenous administration of the drug (pemetrexed) and is measured by taking plasma samples at various timepoints and measuring the amount of pemetrexed in the plasma.","timeFrame":"Cycle 1 and Cycle 2: before the end of infusion (approximately 9.5 minutes), 2 hours, 9-10 hours, 24-48 hours, 480-528 hours (20 to 22 days) after start of pemetrexed infusion"},{"measure":"Pemetrexed Population Pharmacokinetics: Volume of Distribution","description":"Volume of distribution is the theoretical size of the compartment necessary to account for total drug amount in the body if it were present throughout the body in the same concentration found in plasma. Volume of distribution is defined as distribution of pemetrexed in the body and is determined by volume of distribution = dose/drug concentration. By knowing dose and measuring concentration of pemetrexed in plasma, volume was calculated. Central volume (V1) was determined by dose/peak serum level of pemetrexed. Peripheral volume (V2) is sum of all tissue spaces outside the central compartment.","timeFrame":"Cycle 1 and Cycle 2: before the end of infusion (approximately 9.5 minutes), 2 hours, 9-10 hours, 24-48 hours, 480-528 hours (20 to 22 days) after start of pemetrexed infusion"},{"measure":"Discontinuations Due to Adverse Events","description":"Adverse events were coded using the Medical Dictionary for Regulatory Activities, Version 11.0.","timeFrame":"baseline, up to 18 weeks"}],"otherOutcomes":[{"measure":"Overall Tumor Response","description":"Overall tumor response was determined using Response Evaluation Criteria In Solid Tumors (RECIST), which defines when cancer patients improve (\"respond\"), stay the same (\"stabilize\"), or worsen (\"progression\") during treatments.\n\nCR (complete response) = disappearance of all target lesions. PR (partial response) = 30% decrease in the sum of the longest diameter of target lesions.\n\nPD (progressive disease) = 20% increase in the sum of the longest diameter of target lesions.\n\nSD (stable disease) = small changes that do not meet above criteria.","timeFrame":"baseline, up to 18 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of locally advanced or metastatic (Stage III or IV at entry) non-small cell lung cancer (NSCLC) or mesothelioma\n* Presence of third-space fluid (fluid around the lungs or abdomen).\n* Eastern Cooperative Oncology Group Performance Status of 0 or 1.\n* Prior anticancer treatment (except radiation) must be completed at least 3 weeks prior to study enrollment, and the patient must have recovered from the sharp toxic effects the anticancer treatment.\n* Estimated life expectancy of at least 8 weeks.\n\nExclusion Criteria:\n\n* Have received treatment within the last 30 days with a drug that was not a marketed product.\n* Active infection that, in the opinion of the investigator, would not allow the patient to tolerate therapy.\n* Pregnancy.\n* Breast-feeding.\n* Significant weight loss (that is, greater than or equal to 10% of body weight) over the 6 weeks before study entry.\n* Brain metastases.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Copenhagen","zip":"2100","country":"Denmark","geoPoint":{"lat":55.67594,"lon":12.56553}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Hanover","zip":"30625","country":"Germany","geoPoint":{"lat":52.37052,"lon":9.73322}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Madrid","zip":"28041","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}}]},"referencesModule":{"seeAlsoLinks":[{"label":"Lilly Clinical Trial Registry","url":"http://www.lillytrials.com"}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Pemetrexed","description":"Pemetrexed 500 mg/m2 intravenous (IV) every 21 days for 6 cycles"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"31"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"6"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"25"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"2"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"3"}]},{"type":"Progressive Disease","reasons":[{"groupId":"FG000","numSubjects":"15"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"3"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Pemetrexed","description":"Pemetrexed 500 mg/m2 intravenous (IV) every 21 days for 6 cycles"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"31"}]}],"measures":[{"title":"Age Continuous","paramType":"MEDIAN","dispersionType":"FULL_RANGE","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"62.7","lowerLimit":"35.7","upperLimit":"77.5"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"4"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"27"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Caucasian","categories":[{"measurements":[{"groupId":"BG000","value":"30"}]}]},{"title":"Hispanic","categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Spain","categories":[{"measurements":[{"groupId":"BG000","value":"12"}]}]},{"title":"Denmark","categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}]},{"title":"Germany","categories":[{"measurements":[{"groupId":"BG000","value":"13"}]}]}]},{"title":"Diagnosis","description":"Diagnosis of Non-Small Cell Lung Cancer (NSCLC) and mesothelioma were determined by each individual investigator.","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Non-Small Cell Lung Cancer (NSCLC)","categories":[{"measurements":[{"groupId":"BG000","value":"23"}]}]},{"title":"Mesothelioma","categories":[{"measurements":[{"groupId":"BG000","value":"8"}]}]}]},{"title":"Disease Stage","description":"Stage means how big the tumor is and how far it has spread. Stages range from 0 (not spread) to IV (spread throughout the body).","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Stage III (locally advanced disease)","categories":[{"measurements":[{"groupId":"BG000","value":"12"}]}]},{"title":"Stage IV (metastatic disease)","categories":[{"measurements":[{"groupId":"BG000","value":"18"}]}]},{"title":"Unknown","categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}]}]},{"title":"Eastern Cooperative Oncology Group (ECOG) Performance Status","description":"Classifies patients according to their functional impairment. Scores range from 0 (Fully Active) to 5 (Death).","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"0 - Fully Active","categories":[{"measurements":[{"groupId":"BG000","value":"14"}]}]},{"title":"1 - Ambulatory, Restricted Strenuous Activity","categories":[{"measurements":[{"groupId":"BG000","value":"17"}]}]}]},{"title":"Fluid Severity","description":"Mild = (1) pleural effusion detectable on radiological imaging, but less than moderate; (2) ascites detectable only by radiological imaging. Moderate = (1) pleural effusion less than 1/3 of the way up the thorax on 1 side on imaging and obscuring the entire hemidiaphragm on that side; (2) ascites detectable on physical exam (that is, fluid wave is palpable). Severe = (1) pleural effusion more than 1/3 of the way up the thorax on imaging; (2) ascites visibly detectable.\n\nFor Moderate Fluid Severity, there were 13 patients with pleural effusion and 1 patient with ascites.","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Mild","categories":[{"measurements":[{"groupId":"BG000","value":"15"}]}]},{"title":"Moderate","categories":[{"measurements":[{"groupId":"BG000","value":"14"}]}]},{"title":"Severe","categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}]}]},{"title":"Primary Basis for Diagnosis","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Cytological","categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}]},{"title":"Histopathological","categories":[{"measurements":[{"groupId":"BG000","value":"25"}]}]}]},{"title":"Type of Third-Space Fluid","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Pleural Effusion","categories":[{"measurements":[{"groupId":"BG000","value":"30"}]}]},{"title":"Ascites","categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}]}]},{"title":"Body Surface Area","paramType":"MEDIAN","dispersionType":"FULL_RANGE","unitOfMeasure":"meters squared (m^2)","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1.8","lowerLimit":"1.4","upperLimit":"2.3"}]}]}]},{"title":"Height","paramType":"MEDIAN","dispersionType":"FULL_RANGE","unitOfMeasure":"centimeters (cm)","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"171.0","lowerLimit":"147.0","upperLimit":"189.0"}]}]}]},{"title":"Weight","paramType":"MEDIAN","dispersionType":"FULL_RANGE","unitOfMeasure":"kilograms (kg)","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"68.0","lowerLimit":"47.9","upperLimit":"100.0"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"SECONDARY","title":"Number of Participants With Common Toxicity Criteria - National Cancer Institute Grade 3 and Grade 4 Toxicities","description":"Number of participants with laboratory and non-laboratory toxicities possibly related to study drug, which were graded using the Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0) for defining and grading specific adverse events. Grades range from 0 (none) to 5 (death). Grade 3 is severe and Grade 4 is life-threatening.\n\nNOS = Not otherwise specified.","populationDescription":"Patients who received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"baseline, up to 18 weeks","groups":[{"id":"OG000","title":"Pemetrexed","description":"Pemetrexed 500 mg/m2 intravenous (IV) every 21 days for 6 cycles"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"}]}],"classes":[{"title":"Leukocytopenia","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Neutropenia/Granulocytopenia","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Platelets","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Ascites (Non-Malignant)","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Febrile Neutropenia","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Pain Pulmonary/Upper Respiratory-Chest/Thorax NOS","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Pleural Effusion (Non-Malignant)","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}]},{"type":"SECONDARY","title":"Pemetrexed Population Pharmacokinetics (PK): Clearance","description":"Clearance (CL) can be defined as the volume of plasma which is completely cleared of drug (pemetrexed) per unit time. Total body clearance is calculated after intravenous administration of the drug (pemetrexed) and is measured by taking plasma samples at various timepoints and measuring the amount of pemetrexed in the plasma.","populationDescription":"Patients who received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"milliliter per minute (mL/min)","timeFrame":"Cycle 1 and Cycle 2: before the end of infusion (approximately 9.5 minutes), 2 hours, 9-10 hours, 24-48 hours, 480-528 hours (20 to 22 days) after start of pemetrexed infusion","groups":[{"id":"OG000","title":"Pemetrexed","description":"Pemetrexed 500 mg/m2 intravenous (IV) every 21 days for 6 cycles"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.6","spread":"21.4"}]}]}]},{"type":"SECONDARY","title":"Pemetrexed Population Pharmacokinetics: Volume of Distribution","description":"Volume of distribution is the theoretical size of the compartment necessary to account for total drug amount in the body if it were present throughout the body in the same concentration found in plasma. Volume of distribution is defined as distribution of pemetrexed in the body and is determined by volume of distribution = dose/drug concentration. By knowing dose and measuring concentration of pemetrexed in plasma, volume was calculated. Central volume (V1) was determined by dose/peak serum level of pemetrexed. Peripheral volume (V2) is sum of all tissue spaces outside the central compartment.","populationDescription":"Patients who received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Liters (L)","timeFrame":"Cycle 1 and Cycle 2: before the end of infusion (approximately 9.5 minutes), 2 hours, 9-10 hours, 24-48 hours, 480-528 hours (20 to 22 days) after start of pemetrexed infusion","groups":[{"id":"OG000","title":"Pemetrexed","description":"Pemetrexed 500 mg/m2 intravenous (IV) every 21 days for 6 cycles"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"}]}],"classes":[{"title":"Central Volume of Distribution","categories":[{"measurements":[{"groupId":"OG000","value":"6.61","spread":"1.32"}]}]},{"title":"Peripheral Volume of Distribution (V2)","categories":[{"measurements":[{"groupId":"OG000","value":"8.91","spread":"1.68"}]}]},{"title":"Peripheral Volume of Distribution (V3)","categories":[{"measurements":[{"groupId":"OG000","value":"1.26","spread":"0"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Overall Tumor Response","description":"Overall tumor response was determined using Response Evaluation Criteria In Solid Tumors (RECIST), which defines when cancer patients improve (\"respond\"), stay the same (\"stabilize\"), or worsen (\"progression\") during treatments.\n\nCR (complete response) = disappearance of all target lesions. PR (partial response) = 30% decrease in the sum of the longest diameter of target lesions.\n\nPD (progressive disease) = 20% increase in the sum of the longest diameter of target lesions.\n\nSD (stable disease) = small changes that do not meet above criteria.","populationDescription":"Patients who received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"baseline, up to 18 weeks","groups":[{"id":"OG000","title":"Pemetrexed","description":"Pemetrexed 500 mg/m2 intravenous (IV) every 21 days for 6 cycles"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"}]}],"classes":[{"title":"Complete Response","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Partial Response","categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]},{"title":"Stable Disease","categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}]},{"title":"Progressive Disease","categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}]},{"title":"Unknown","categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}]}]},{"type":"SECONDARY","title":"Discontinuations Due to Adverse Events","description":"Adverse events were coded using the Medical Dictionary for Regulatory Activities, Version 11.0.","populationDescription":"Patients who received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"baseline, up to 18 weeks","groups":[{"id":"OG000","title":"Pemetrexed","description":"Pemetrexed 500 mg/m2 intravenous (IV) every 21 days for 6 cycles"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"}]}],"classes":[{"title":"Atrial fibrillation","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Febrile neutropenia (possibly related)","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Pneumonia (resulted in death)","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Respiratory failure (resulted in death)","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}]},{"type":"PRIMARY","title":"Overview of Adverse Events","description":"Any untoward medical occurrence in a patient who received study drug was considered an adverse event (AE), without regard to possibility of causal relationship. Treatment-emergent adverse events (TEAE): those which occurred or worsened after baseline. An adverse event resulting in any of the following outcomes, or deemed to be significant for any other reason, was considered to be a serious adverse event (SAE): death; initial or prolonged inpatient hospitalization; a life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.","populationDescription":"Patients who received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"baseline, up to 18 weeks","groups":[{"id":"OG000","title":"Pemetrexed","description":"Pemetrexed 500 mg/m2 intravenous (IV) every 21 days for 6 cycles"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"}]}],"classes":[{"title":"TEAE - All, regardless of causality","categories":[{"measurements":[{"groupId":"OG000","value":"28"}]}]},{"title":"TEAE - Possibly related to study drug","categories":[{"measurements":[{"groupId":"OG000","value":"23"}]}]},{"title":"SAE - All, regardless of causality","categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}]},{"title":"SAE - Possibly related to study drug","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Discontinuations Due to SAEs (including death)","categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]},{"title":"Discontinuations - Possibly related to study drug","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Discontinuations Due to Nonserious AEs","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Deaths - On Study","categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]},{"title":"Deaths - Possibly related to study drug","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Deaths - Within 30 days of Study Discontinuation","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","eventGroups":[{"id":"EG000","title":"Pemetrexed","description":"Pemetrexed 500 mg/m2 intravenous (IV) every 21 days for 6 cycles","seriousNumAffected":12,"seriousNumAtRisk":31,"otherNumAffected":28,"otherNumAtRisk":31}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":31}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":31}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":31}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":31}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":31}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":31}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":31}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":31}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":31}]},{"term":"Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":31}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":31}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":31}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":31}]},{"term":"Acute pulmonary oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":31}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":31}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":31}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":31}]},{"term":"Pericardial excision","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":31}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":31}]},{"term":"Lymphopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":31}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":31}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":31}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":31}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":31}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":10,"numAtRisk":31}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":31}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":8,"numAtRisk":31}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":31}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":9,"numAtRisk":31}]},{"term":"Influenza like illness","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":31}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":31}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":31}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":31}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":3,"numAtRisk":31}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":31}]},{"term":"Anorexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":31}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":31}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":31}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":31}]},{"term":"Tumour pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":31}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":31}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":31}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":31}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":31}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":31}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":31}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":31}]},{"term":"Dermatitis acneiform","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":31}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":31}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":31}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","phone":"800-545-5979"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","removedCountries":["United Kingdom"]},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"},{"id":"D008654","term":"Mesothelioma"},{"id":"D008175","term":"Lung Neoplasms"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"},{"id":"D000236","term":"Adenoma"},{"id":"D009375","term":"Neoplasms, Glandular and Epithelial"},{"id":"D009370","term":"Neoplasms by Histologic Type"},{"id":"D018301","term":"Neoplasms, Mesothelial"}]},"interventionBrowseModule":{"meshes":[{"id":"D000068437","term":"Pemetrexed"}],"ancestors":[{"id":"D006147","term":"Guanine"},{"id":"D007042","term":"Hypoxanthines"},{"id":"D011688","term":"Purinones"},{"id":"D011687","term":"Purines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D005971","term":"Glutamates"},{"id":"D024342","term":"Amino Acids, Acidic"},{"id":"D000596","term":"Amino Acids"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D000600","term":"Amino Acids, Dicarboxylic"}]}},"hasResults":true}